Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Alpuente

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Headache and Pain|December 14, 2021
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence studyAlicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
The Journal of Headache and Pain|October 8, 2021
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 monthsEdoardo Caronna, Victor José Gallardo, Alicia Alpuente, et al.
Cephalalgia : an International Journal of Headache|February 15, 2020
Have the IHS <i>Guidelines for controlled trials of acute treatment of migraine attacks</i> been followed? Laying the ground for the 4th editionAlicia Alpuente, Cristina Tassorelli, Hans-Christoph Diener, et al.
Headache|February 23, 2020
Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational StudyAlicia Alpuente, Víctor José Gallardo, Marta Torres-Ferrús, et al.
Annals of Neurology|September 2, 2022
Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in MigraineAlicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
Cephalalgia : an International Journal of Headache|October 4, 2021
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacksAlicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
The Journal of Headache and Pain|April 18, 2024
Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterizationAlicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
Cephalalgia : an International Journal of Headache|September 24, 2024
Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety dataIker Elosua-Bayes, Alicia Alpuente, Laura Melgarejo, et al.
Journal of Neurology|March 27, 2021
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational studyMarta Torres-Ferrús, Victor J Gallardo, Alicia Alpuente, et al.
European Journal of Neurology|April 11, 2023
Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcomeMarta Torres-Ferrus, Victor J Gallardo, Alicia Alpuente, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Headache and Pain|December 14, 2021
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence studyAlicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
The Journal of Headache and Pain|October 8, 2021
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 monthsEdoardo Caronna, Victor José Gallardo, Alicia Alpuente, et al.
Cephalalgia : an International Journal of Headache|February 15, 2020
Have the IHS <i>Guidelines for controlled trials of acute treatment of migraine attacks</i> been followed? Laying the ground for the 4th editionAlicia Alpuente, Cristina Tassorelli, Hans-Christoph Diener, et al.
Headache|February 23, 2020
Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational StudyAlicia Alpuente, Víctor José Gallardo, Marta Torres-Ferrús, et al.
Annals of Neurology|September 2, 2022
Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in MigraineAlicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
Cephalalgia : an International Journal of Headache|October 4, 2021
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacksAlicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
The Journal of Headache and Pain|April 18, 2024
Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterizationAlicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
Cephalalgia : an International Journal of Headache|September 24, 2024
Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety dataIker Elosua-Bayes, Alicia Alpuente, Laura Melgarejo, et al.
Journal of Neurology|March 27, 2021
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational studyMarta Torres-Ferrús, Victor J Gallardo, Alicia Alpuente, et al.
European Journal of Neurology|April 11, 2023
Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcomeMarta Torres-Ferrus, Victor J Gallardo, Alicia Alpuente, et al.
Pageof 6